Single Agent Therapy

Phase 2

Single Agent Therapy is one of 87 therapeutic programs targeting Hematopoietic and Lymphatic System Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hematopoietic and Lymphatic System NeoplasmNot yet recruiting

GliomaRecruiting

InsomniaNot yet recruiting

Hematopoietic and Lymphatic System NeoplasmPreclinical

Not yet recruiting

GliomaPhase 1

Recruiting

InsomniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Camptosar

Pfizer

Phase 2

5 7

Verzenio

Eli Lilly

Phase 2

3 8

Dostarlimab

Incyte

Phase 2

2 9

Lexapro

AbbVie

Phase 2

1 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Insomnia

NCT07565974

Phase 1Recruiting

Glioma

NCT07025226

Q4 2027

PreclinicalNot yet recruiting

Hematopoietic and Lymphatic System Neoplasm

NCT07658677

Clinical

Trials by Indication[1]

Insomnia1 trial

MC251001 - Phase II Randomized Double-Blinded Pilot Study of THC vs. THC/CBD (1:1) vs. Placebo for Insomnia in Patients With Cancer

Not yet recruiting·MMayo Clinic·Phase 2·NCT07565974·69 enrolled

Glioma1 trial

MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

Recruiting·MMayo Clinic·Phase 1·NCT07025226·30 enrolled

Hematopoietic and Lymphatic System Neoplasm1 trial

Piloting a Novel Therapeutic for Sleep Disturbance in Palliative Care Over 5 Weeks: The PILLOW Study

Not yet recruiting·TTheodore Brasky PhD·Preclinical·NCT07658677·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Single Agent Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Single Agent Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Theodore Brasky PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTheodore Brasky PhD

Single Agent Therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Insomnia1 trial

Glioma1 trial

Hematopoietic and Lymphatic System Neoplasm1 trial

References

Drug Info

Quick Facts

Related News